In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
出版年份 2013 全文链接
标题
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
作者
关键词
-
出版物
JOURNAL OF INFECTIOUS DISEASES
Volume 209, Issue 5, Pages 668-675
出版商
Oxford University Press (OUP)
发表日期
2013-10-24
DOI
10.1093/infdis/jit562
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients
- (2013) Paul J. Pockros et al. HEPATOLOGY
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients
- (2013) Heiner Wedemeyer et al. HEPATOLOGY
- Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir
- (2012) S. Le Pogam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
- (2012) Jean-Michel Pawlotsky et al. ANTIVIRAL THERAPY
- Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays
- (2012) T. Verbinnen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS
- (2012) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
- (2011) Fernando E. Membreno et al. Clinics in Liver Disease
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- (2011) Marc G. Ghany et al. HEPATOLOGY
- New NS5B polymerase inhibitors for hepatitis C
- (2010) Florence Legrand-Abravanel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients
- (2010) Sophie Le Pogam et al. JOURNAL OF INFECTIOUS DISEASES
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
- (2010) Edward J Gane et al. LANCET
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients
- (2009) Simone Susser et al. HEPATOLOGY
- Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
- (2008) Silvana Gaudieri et al. HEPATOLOGY
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
- (2008) Thomas Kuntzen et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started